1. Howaldt S, et al. Presented at UEGW 2019, abstract number OP195. 2. Lugg et al. 2014 Journal of Crohn's and Colitis 8, 876-880 3. Shield Study ST10-01-304 Headline Results 4(th) March 2019: "A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous ferric carboxymaltose, for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease" 4. FERACCRU() UK Summary of Product Characteristics, Norgine B.V. January 2019. Available at: https://www.medicines.org.uk/emc/product... [https://www.medicines.org.uk/emc/product...] Accessed October 2019 5. Gasche C, et al. Inflamm Bowel Dis 2015; 21 (3): 579-588 Available at https://www.ncbi.nlm.nih.gov/pubmed/2554... [https://www.ncbi.nlm.nih.gov/pubmed/2554...] Accessed October 2019 6. Schmidt C, et al. Aliment Pharmacol Ther. 2016 Aug;44(3): 259-270.
GL/COR/1019/0199 , Date of preparation October 2019
Logo -- http://mma.prnewswire.com/media/597589/N... [http://mma.prnewswire.com/media/597589/N...]
CONTACT: For further information or an interview with Dr. StefanieHowaldt, Principal Investigator of the study please contact: EleniFistikaki +44 (0)1895826227 or +44 (0)7825 389477, Clara Bentham +44(0)1895 826654 or +44 (0)7734 367883, contact@norgine.com
